Inosine-5′-diphosphoric acid disodium salt | CAS:54735-61-4

We serve Inosine-5′-diphosphoric acid disodium salt CAS:54735-61-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Inosine-5'-diphosphoric acid disodium salt

Chemical Name:Inosine-5'-diphosphoric acid disodium salt
CAS.NO:54735-61-4
Synonyms:Inosine-5'-diphosphoric acid disodium salt
5'-Idp-Na2
Idp-Na2
 
Physical and Chemical Properties:
Boiling Point 925.2ºC at 760 mmHg
Molecular Formula C10H12N4Na2O11P2
Molecular Weight 472.150
Flash Point 513.3ºC
 
Description:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:5kg/bag
Storage:Store in a cool, ventilated place
Use: This product belongs to the nucleotide products,and can be used as biochemical reagent and intermediate for the production nucleotide drugs.And it can be used for the production of PolyI, PolyI:C.



Contact us for information like Citicoline sodium chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Idp-Na2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Idp-Na2 Use and application,CDPC technical grade,usp/ep/jp grade.


Related News: Citizens and residents will be allowed entry to New Zealand, but will be required to quarantine themselves for 14 days, Prime Minister Jacinda Ardern said.Dibutyl maleate manufacturer As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.(1-ethylpyrrolidin-2-yl)methanamine supplier As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.1,6-DIIODOHEXANE vendor Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer.